TerrAscend

US Cannabis Legalization And Digital Health Will Unlock Opportunities

AnalystHighTarget

Not Invested

Community Contributor

Published

10 Aug 25

AnalystHighTarget's Fair Value

CA$2.25

50.3% undervalued

10 Sep

CA$1.12

-29.1%

-5.1%

-29.1%

-5.1%

You can edit this narrative until Aug 10 10:29 PM. Then, changes will post as Updates.

Author's Valuation

CA$2.2550.3% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

CA$2.25

50.3% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

3.73%

Pharma revenue growth rate

0.68%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.30%

Calculation

US$3.08m

Earnings '28

223.42x

PE Ratio '28

US$687.20m

Market Cap '28

US$687.20m

Market Cap '28

352.20m

No. shares '28

US$1.95

Share Price '28

US$1.95 Share Price '28

Discounted to 2025 @ 6.30% p.a.

US$1.62

Fair Value '25

US$1.62 Fair Value '25

Converted to CAD @ 1.3864 USD/CAD Exchange Rate

CA$2.25

Fair Value '25